Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02089932 |
Recruitment Status :
Completed
First Posted : March 18, 2014
Last Update Posted : January 15, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dexmedetomidine Femoral Nerve Block Arthroscopic Knee Surgery | Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | The Effects of Different Dose Levels of Peri-neural Dexmedetomidine on the Pharmacodynamic and Side Effects Profiles of Bupivacaine-induced Ultrasound-guided Femoral Nerve Block |
Study Start Date : | February 2014 |
Actual Primary Completion Date : | April 2015 |
Actual Study Completion Date : | June 2015 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: group B: control bupivacaine group
Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
|
Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia. Drug: Placebo |
Experimental: Group B-DEX 25 : Peri-neural Dexmedetomidine
Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
|
Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia. |
Experimental: Group B-DEX 50:Peri-neural Dexmedetomidine
Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
|
Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia. |
Experimental: Group B-DEX 75:Peri-neural Dexmedetomidine
Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
|
Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia. |
- duration of sensory block [ Time Frame: Every 5 minutes for the first 30 minutes after end of study medications injection, then postoperatively every 2 hours till complete recovery of normal sensation. ]the time interval between the onset of the sensory block and the complete resolution of normal sensation. Over a period of 30 min after injection of the study medications and every 2 hours postoperatively till complete recovery of normal sensation; a blinded investigator will assess sensory block with pinprick test using a 3-point scale: 0 ═ complete loss of sensation, 1 ═ partial loss of sensation and 2 ═ normal sensation. Pinprick test will be done in comparison to the contralateral area at the sensory distribution of the femoral nerve.
- Time to first request of postoperative rescue analgesic [ Time Frame: over the first postoperative 24hours ]the time interval between the onset of successful sensory block and the first request to postoperative analgesia
- Onset of sensory block [ Time Frame: up to 30 minutes after the end of injection ]the time elapsed between the end of injection and the development of complete sensory block
- Onset of motor block [ Time Frame: up to 30 minutes after the end of injection ]the time elapsed between the end of injection and the development of complete motor block
- visual analogue pain scores (VAS) [ Time Frame: 2hours post operative and for 24hours ]Visual analogue pain scores (resting and dynamic VAS) will be assessed at 2, 4, 6, 8, 12, 16, and 24 hours postoperatively.
- Richmond Agitation-Sedation Score (RASS) [ Time Frame: 2hours post operative and for 24hours ]Richmond Agitation-Sedation Score (RASS) will be assessed at 2, 4, 6, 8, 12, 16, and 24 hours postoperatively.
- duration of motor block [ Time Frame: Every 5 minutes for the first 30 minutes after end of study medications injection, then postoperatively every 2 hours till complete recovery of motor power. ]The time interval between the onset of the motor block and the complete resolution of the motor power in quadriceps muscle. Over a period of 30 min after injection of the study medications and every 2 hours postoperatively till complete recovery of motor power; a blinded investigator will assess the motor block using a 3-point scale where: 0 ═ no movement, 1 ═ reduced motor strength, but some perceptible movement, and 2 ═ normal motor function.
- total morphine consumption [ Time Frame: The first 24 hours postoperatively ]The total dose of morphine needed by the patient postoperatively till 24 hours.
- perioperative hemodynamic parameters [ Time Frame: will be recorded at 0, 15, 30 minutes after femoral nerve block, then every 10 minutes intraoperatively, and every 2 hours postoperative for a period of 12 hours. ]Vital signs (heart rate and arterial blood pressure) will be recorded at 0, 15, 30 minutes after femoral nerve block, then every 10 minutes intraoperatively, and every 2 hours postoperative for a period of 12 hours.
- incidence of side effects. [ Time Frame: from the injection time till 24 hours postoperatively ]Adverse events will be defined as hypotension (a 30% decrease in systolic blood pressure in relation to the baseline value), bradycardia (heart rate less than 60 beats per minute), desaturation (SpO2 < 90% on room air) and postoperative nausea and/or vomiting.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 45 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- all patients with ASA physical status I or II, scheduled for arthroscopic knee surgery
Exclusion Criteria:
- Patients who are refusing regional block, patients with diabetic peripheral neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture site, and history of allergic reaction to study medications

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089932
Egypt | |
Kasr Al Ainy | |
Cairo, Egypt, 11562 |
Study Chair: | Mohamed Abdulatif, Professor of Anesthesia | Cairo University |
Responsible Party: | Heba Nassar,MD, lecturer of anesthesia, Cairo University |
ClinicalTrials.gov Identifier: | NCT02089932 |
Other Study ID Numbers: |
N-60-2013 |
First Posted: | March 18, 2014 Key Record Dates |
Last Update Posted: | January 15, 2019 |
Last Verified: | January 2019 |
femoral nerve block peri-neural dexmedetomidine |
Dexmedetomidine Bupivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Hypnotics and Sedatives |
Analgesics, Non-Narcotic Analgesics Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |